title: Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.
abstract: OBJECTIVE
  To analyze the outcome and dose distribution of intensity-modulated radiation therapy (IMRT) by helical tomotherapy in women treated for large supradiaphragmatic Hodgkin's disease.
  
  
  METHODS
  A total of 13 patients received adjuvant radiation at a dose of 30 Gy to the initially involved sites with a boost of 6 Gy to those areas suspected of harboring residual disease on the simulation CT scan.
  
  
  RESULTS
  With a median follow-up of 23 months, the two-year progression-free survival was 91.6%, and the 2- and 3-year overall survivals were 100%. We did not report any heart or lung acute side effects. The conformity index of PTV (Planning Target Volume) was better for IMRT than for 3D-CRT (p=0.001). For the breasts, lungs, heart, thyroid and esophagus, the volume distributions favored the IMRT plans. For the breasts, the V(20Gy), V(25Gy) and V(30Gy) were 1.5, 2.5 and 3.5 times lower, respectively, for IMRT than for 3D-CRT. For the lung tissues, the V(20Gy) and V(30Gy) were 2 times and 4.5 times lower, respectively, for IMRT than for 3D-CRT. For the heart, the V(20Gy) and V(30Gy) were 1.4 and 2 times lower, respectively, for IMRT than for 3D-CRT. For the esophagus, the V(35Gy) was 1.7 lower for IMRT than for 3D-CRT, and for the thyroid, the V(30Gy) was 1.2 times lower for IMRT.
  
  
  CONCLUSIONS
  IMRT by helical tomotherapy improved the PTV coverage and dramatically decreased the dose in organs at risk. The treatment was well tolerated, but a longer follow-up is necessary to prove a translation of these dosimetric improvements in the outcome of the patients.
authors: Delphine
authors: D
authors: Antoni
authors: Shanti
authors: S
authors: Natarajan-Ame
authors: Philippe
authors: P
authors: Meyer
authors: Claudine
authors: C
authors: Niederst
authors: Khalil
authors: K
authors: Bourahla
authors: Georges
authors: G
authors: Noel
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D055815:Young Adult
references: Radiother Oncol. 1996 Jan;38(1):25-31
references: 8850423
references: Chest. 1997 Jun;111(6):1718-23
references: 9187199
references: Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):333-42
references: 16414369
references: Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1522-7
references: 21705151
references: J Natl Cancer Inst. 2007 Feb 21;99(4):300-8
references: 17312307
references: N Engl J Med. 2007 Nov 8;357(19):1916-27
references: 17989384
references: Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):490-7
references: 20800383
references: J Clin Oncol. 2000 Feb;18(3):498-509
references: 10653865
references: Cancer Treat Rev. 2000 Aug;26(4):291-302
references: 10913384
references: J Natl Cancer Inst. 1993 Jan 6;85(1):25-31
references: 8416252
references: J Clin Oncol. 2000 Apr;18(7):1492-9
references: 10735897
references: Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9
references: 10487552
references: Blood. 2011 Feb 10;117(6):1806-16
references: 21037086
references: Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):199-205
references: 21481723
references: N Engl J Med. 1996 Mar 21;334(12):745-51
references: 8592547
references: J Clin Oncol. 2001 Nov 15;19(22):4238-44
references: 11709567
references: J Natl Cancer Inst. 2001 Apr 18;93(8):618-29
references: 11309438
references: Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):865-70
references: 9128963
references: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007110
references: 21328291
references: J Clin Oncol. 2000 Feb;18(3):487-97
references: 10653864
references: Med Pediatr Oncol. 1989;17(6):477-84
references: 2586362
references: N Engl J Med. 2010 Aug 12;363(7):640-52
references: 20818855
references: Radiother Oncol. 2009 Apr;91(1):4-15; discussion 1-3
references: 19201045
references: Ann Oncol. 2006 Dec;17(12):1749-60
references: 16984979
references: Radiat Res. 2007 Jan;167(1):12-42
references: 17214511
references: Radiother Oncol. 2008 Aug;88(2):202-10
references: 18555548
references: Sci Am. 2003 Sep;289(3):28-30
references: 12951822
references: N Engl J Med. 2012 Feb 2;366(5):399-408
references: 22149921
references: Radiother Oncol. 2007 Nov;85(2):178-86
references: 17719110
references: N Engl J Med. 2006 Oct 12;355(15):1572-82
references: 17035650
references: Blood. 2006 Apr 1;107(7):2912-9
references: 16339404
references: Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):724-35
references: 12573760
references: Radiother Oncol. 2008 May;87(2):281-9
references: 18279984
references: Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1057-65
references: 23200817
references: Hematology Am Soc Hematol Educ Program. 2007;:192-6
references: 18024629
references: Cancer. 2005 Aug 15;104(4):856-63
references: 15981282
references: BMJ. 1994 Jul 16;309(6948):162-6
references: 8044095
references: Strahlenther Onkol. 2008 Aug;184(8):406-10
references: 18956517
references: Ann Oncol. 2002;13 Suppl 1:79-83
references: 12078908
references: BMC Med Phys. 2012 Jun 28;12:2
references: 22742393
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
references: 20171502
references: J Clin Oncol. 2001 Jul 1;19(13):3163-72
references: 11432882
references: J Clin Oncol. 2007 Aug 10;25(23):3495-502
references: 17606976
references: Oncology. 1999 Oct;57(3):224-31
references: 10545791
references: Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e145-52
references: 21605948
references: Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):69-74
references: 18538497
references: Radiat Oncol. 2010 May 11;5:33
references: 20459790
references: Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):876-83
references: 19386434
references: J Natl Cancer Inst. 2002 Feb 6;94(3):182-92
references: 11830608
references: Blood. 2002 Jun 15;99(12):4257-64
references: 12036851
references: Semin Radiat Oncol. 2007 Jul;17(3):206-22
references: 17591568
references: Strahlenther Onkol. 2002 Jul;178(7):357-62
references: 12163989
references: AJR Am J Roentgenol. 2008 Jul;191(1):32-7
references: 18562721
references: Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):959-64
references: 23021709
references: Radiother Oncol. 2006 Jun;79(3):270-7
references: 16797755
references: Br J Haematol. 2011 Jul;154(1):23-31
references: 21539537
references: J Clin Oncol. 1996 May;14(5):1442-6
references: 8622057
references: J Natl Cancer Inst. 2003 Jul 2;95(13):971-80
references: 12837833
references: Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1173-80
references: 19386423
references: Radiother Oncol. 2011 Aug;100(2):167-75
references: 21752480
references: Radiother Oncol. 2008 Apr;87(1):82-8
references: 18037182
references: Am J Clin Oncol. 2009 Jun;32(3):262-8
references: 19433968
references: Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):24-33
references: 18722263
references: J Clin Oncol. 2001 Mar 15;19(6):1610-8
references: 11250989
references: JAMA. 2003 Jul 23;290(4):465-75
references: 12876089
references: Blood. 2002 Sep 15;100(6):1989-96
references: 12200357
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
references: 20171521
references: J Clin Oncol. 2006 Jul 1;24(19):3128-35
references: 16754934
references: Eur J Cancer. 1997 Apr;33(4):526-30
references: 9274430
references: Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):313-6
references: 12243802
references: J Clin Oncol. 2004 Jul 15;22(14):2835-41
references: 15199092